시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 비낭포성 섬유증 기관지확장증 시장 보고서(2025년)
Non-Cystic Fibrosis Bronchiectasis Global Market Report 2025
상품코드 : 1825836
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

비낭포성 섬유증 기관지확장증 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.1%로 46억 8,000만 달러로 성장할 것입니다. 예측 기간의 성장은 맞춤형 의료의 발전, 새로운 바이오마커의 출현, 호흡기 의료에 대한 투자 증가, 연구개발 확대, 공중보건에 대한 노력, 전 세계적인 고령화, 표적 치료제 개발 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 디지털 헬스 솔루션, 표적치료에 대한 집중, AI와 머신러닝의 통합, 재택의료로의 전환, 환자 중심 접근법, 모바일 헬스(모바일 헬스) 솔루션의 성장 등이 있습니다.

향후 5년간 6.1%의 성장률 전망은 지난번 예측보다 0.6% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰로 인해 네덜란드와 캐나다에서 개발된 분무기 및 건조 분말 흡입기의 가격이 급등하고, 호흡기 치료의 순응도가 떨어지고, 호흡기 내과 비용이 상승하여 미국에서 흡입 점액 용해 요법의 채택을 저해할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

비낭포성 섬유증 기관지확장증 시장은 호흡기질환의 유병률 증가로 인해 성장할 것으로 예상됩니다. 이러한 질환은 폐와 호흡기 기능에 영향을 미치는 다양한 증상을 포함하며, 담배연기 등 실외와 실내 모두에서 환경오염이 심해짐에 따라 악화되고 있습니다. 호흡기 감염증의 증가는 표적화된 개입과 공중보건 노력을 통해 비낭포성 섬유증 기관지확장증에 대한 이해, 진단 및 관리를 발전시킬 수 있는 기회를 제공합니다. 영국 Office for Health Improvement and Disparities가 2023년 6월에 발표한 최근 데이터에 따르면, 2022-2023년 시즌 영국에서 성홍열 A군 용혈성 연쇄상구균 신고 건수가 크게 증가하여 호흡기질환의 증가 추세가 강조되고 있습니다. 이러한 추세는 비낭포성 섬유증 기관지확장증 시장의 성장 예측을 뒷받침하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Non-cystic fibrosis bronchiectasis is a persistent condition marked by permanent widening and abnormality of the airways (bronchi) in the lungs. This results from recurrent inflammation and infections, which weaken and damage the walls of the bronchial tubes. Symptoms include mucus buildup, chronic coughing, breathlessness, and frequent respiratory infections. Treatment typically focuses on symptom management, preventing flare-ups, and addressing underlying factors such as bacterial infections or immune system dysfunction.

Diagnosis of non-cystic fibrosis bronchiectasis involves various methods including computed tomography (CT) scans, bronchoscopies, chest X-rays, lung function tests, sputum culture, and blood tests. CT scans provide detailed lung images that help in diagnosing bronchiectasis by revealing the extent and location of lung damage. Treatment options are categorized into surgical interventions, physiotherapy, vaccinations, airway pharmacotherapy, antibiotics, and others. These treatments are utilized across different healthcare settings such as hospitals, clinics, and ambulatory care centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The non-cystic fibrosis bronchiectasis market research report is one of a series of new reports from the business research company that provides non-cystic fibrosis bronchiectasis market statistics, including non-cystic fibrosis bronchiectasis industry global market size, regional shares, competitors with an non-cystic fibrosis bronchiectasis market share, detailed non-cystic fibrosis bronchiectasis market segments, market trends and opportunities, and any further data you may need to thrive in the non-cystic fibrosis bronchiectasis industry. This non-cystic fibrosis bronchiectasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-cystic fibrosis bronchiectasis market size has grown strongly in recent years. It will grow from $3.5 billion in 2024 to $3.7 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rising incidence and prevalence, advances in diagnostic technologies, growing geriatric population, government support and funding, improved healthcare infrastructure, increased diagnosis awareness, rising geriatric population, environmental exposure.

The non-cystic fibrosis bronchiectasis market size is expected to see strong growth in the next few years. It will grow to $4.68 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to advances in personalized medicine, the emergence of new biomarkers, increased investment in respiratory medicine, growing research and development, public health initiatives, the global aging population, and the development of targeted therapies. Major trends in the forecast period include digital health solutions, a focus on targeted therapies, the integration of AI and machine learning, a shift towards home-based care, patient-centric approaches, and the growth of mobile health (mHealth) solutions.

The forecast of 6.1% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of inhaled mucolytic therapies by inflating prices of nebulizers and dry powder inhalers developed in the Netherlands and Canada, resulting in reduced respiratory therapy adherence and higher pulmonology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The non-cystic fibrosis bronchiectasis market is poised for growth due to the increasing incidence of respiratory diseases. These diseases encompass various conditions affecting lung and respiratory function, exacerbated by rising environmental pollution, both outdoors and indoors, such as tobacco smoke. The uptick in respiratory infections presents opportunities for advancing the understanding, diagnosis, and management of non-cystic fibrosis bronchiectasis through targeted interventions and public health initiatives. Recent data from a June 2023 report by the UK's Office for Health Improvement and Disparities highlighted a significant rise in scarlet fever Group A Streptococcus bacteria notifications during the 2022-2023 season in England, underscoring the escalating trend in respiratory illnesses. This trend underscores the anticipated growth in the non-cystic fibrosis bronchiectasis market.

Leading companies in the non-cystic fibrosis bronchiectasis market are increasingly adopting personalized medicine strategies, particularly through innovations such as nebulization solutions, to enhance the efficiency of drug delivery and improve patient adherence. Nebulization technologies represent a cutting-edge approach for precise administration of respiratory medications, thereby boosting treatment adherence and overall therapeutic outcomes. For example, in April 2022, Zambon S.P.A., a prominent pharmaceutical firm based in Italy, secured a designation from the US FDA for CMS I-neb therapy aimed at patients suffering from non-cystic fibrosis bronchiectasis (NCFB). This therapy is investigational and potentially revolutionary as an inhaled treatment for adult NCFB patients infected with P. aeruginosa, a significant milestone in advancing treatment options for this chronic and progressive respiratory condition. The breakthrough designation underscores the accelerated development and regulatory review pathway for CMS I-neb in NCFB.

In November 2023, Chiesi Farmaceutici SpA, an Italian pharmaceutical company, announced a partnership with Haisco Pharmaceutical Group Co., Ltd. This collaboration focuses on Haisco's commercialization of Chiesi's investigational bronchiectasis drug in China. Haisco will provide financial and logistical support to facilitate regulatory approval, marketing, and distribution efforts necessary for introducing the bronchiectasis treatment to the Chinese market. Haisco Pharmaceutical Group Co. Ltd., based in China, specializes in developing treatments for respiratory diseases, including bronchiectasis.

Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc, Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd, Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc, Insmed Incorporated, Genentech, Zydus Cadila, Santhera Pharmaceuticals, TSRL Inc

North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2024. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-cystic fibrosis bronchiectasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-cystic fibrosis bronchiectasis market consists of revenues earned by entities by providing services such as diagnostic imaging, pulmonary function testing, medical consultations, home healthcare, pulmonary rehabilitation, and management of chronic respiratory infections through pharmaceutical treatments and advanced therapeutic technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-cystic fibrosis bronchiectasis market also includes sales of antibiotics, bronchodilators, mucolytics, inhalers, nebulizers, airway clearance devices, and respiratory monitoring devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Cystic Fibrosis Bronchiectasis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-cystic fibrosis bronchiectasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for non-cystic fibrosis bronchiectasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-cystic fibrosis bronchiectasis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Non-Cystic Fibrosis Bronchiectasis Market Characteristics

3. Non-Cystic Fibrosis Bronchiectasis Market Trends And Strategies

4. Non-Cystic Fibrosis Bronchiectasis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Non-Cystic Fibrosis Bronchiectasis Growth Analysis And Strategic Analysis Framework

6. Non-Cystic Fibrosis Bronchiectasis Market Segmentation

7. Non-Cystic Fibrosis Bronchiectasis Market Regional And Country Analysis

8. Asia-Pacific Non-Cystic Fibrosis Bronchiectasis Market

9. China Non-Cystic Fibrosis Bronchiectasis Market

10. India Non-Cystic Fibrosis Bronchiectasis Market

11. Japan Non-Cystic Fibrosis Bronchiectasis Market

12. Australia Non-Cystic Fibrosis Bronchiectasis Market

13. Indonesia Non-Cystic Fibrosis Bronchiectasis Market

14. South Korea Non-Cystic Fibrosis Bronchiectasis Market

15. Western Europe Non-Cystic Fibrosis Bronchiectasis Market

16. UK Non-Cystic Fibrosis Bronchiectasis Market

17. Germany Non-Cystic Fibrosis Bronchiectasis Market

18. France Non-Cystic Fibrosis Bronchiectasis Market

19. Italy Non-Cystic Fibrosis Bronchiectasis Market

20. Spain Non-Cystic Fibrosis Bronchiectasis Market

21. Eastern Europe Non-Cystic Fibrosis Bronchiectasis Market

22. Russia Non-Cystic Fibrosis Bronchiectasis Market

23. North America Non-Cystic Fibrosis Bronchiectasis Market

24. USA Non-Cystic Fibrosis Bronchiectasis Market

25. Canada Non-Cystic Fibrosis Bronchiectasis Market

26. South America Non-Cystic Fibrosis Bronchiectasis Market

27. Brazil Non-Cystic Fibrosis Bronchiectasis Market

28. Middle East Non-Cystic Fibrosis Bronchiectasis Market

29. Africa Non-Cystic Fibrosis Bronchiectasis Market

30. Non-Cystic Fibrosis Bronchiectasis Market Competitive Landscape And Company Profiles

31. Non-Cystic Fibrosis Bronchiectasis Market Other Major And Innovative Companies

32. Global Non-Cystic Fibrosis Bronchiectasis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Cystic Fibrosis Bronchiectasis Market

34. Recent Developments In The Non-Cystic Fibrosis Bronchiectasis Market

35. Non-Cystic Fibrosis Bronchiectasis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기